| Literature DB >> 33719426 |
Juergen Ramharter1, Dirk Kessler1, Peter Ettmayer1, Marco H Hofmann1, Thomas Gerstberger1, Michael Gmachl1, Tobias Wunberg1, Christiane Kofink1, Michael Sanderson1, Heribert Arnhof1, Gerd Bader1, Klaus Rumpel1, Andreas Zöphel1, Renate Schnitzer1, Jark Böttcher1, Jonathan C O'Connell2, Rachel L Mendes2, David Richard2, Nikolai Pototschnig1, Irene Weiner1, Wolfgang Hela1, Katja Hauer1, Daniela Haering1, Lyne Lamarre1, Bernhard Wolkerstorfer1, Christian Salamon1, Patrick Werni1, Silvia Munico-Martinez1, Reiner Meyer1, Matthew D Kennedy1, Norbert Kraut1, Darryl B McConnell1.
Abstract
KRAS, the most common oncogenic driver in human cancers, is controlled and signals primarily through protein-protein interactions (PPIs). The interaction between KRAS and SOS1, crucial for the activation of KRAS, is a typical, challenging PPI with a large contact surface area and high affinity. Here, we report that the addition of only one atom placed between Y884SOS1 and A73KRAS is sufficient to convert SOS1 activators into SOS1 inhibitors. We also disclose the discovery of BI-3406. Combination with the upstream EGFR inhibitor afatinib shows in vivo efficacy against KRASG13D mutant colorectal tumor cells, demonstrating the utility of BI-3406 to probe SOS1 biology. These findings challenge the dogma that large molecules are required to disrupt challenging PPIs. Instead, a "foot in the door" approach, whereby single atoms or small functional groups placed between key PPI interactions, can lead to potent inhibitors even for challenging PPIs such as SOS1-KRAS.Entities:
Year: 2021 PMID: 33719426 DOI: 10.1021/acs.jmedchem.0c01949
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446